34 results about "Lysin" patented technology

The invention discloses a piglet intestinal health targeting probiotic engineering bacterium compound as well as preparation and application thereof. The compound is FP (at) EcN-pnirNKL, wherein a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin, and a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin; b) the recombinant plasmid pnirBMisL-NK-Lysin comprises an NK-Lysin gene optimized by a codon, and the NK-Lysin gene is integrated into the anaerobic inducible plasmid pnirBMisL through homologous recombination; c) the FP is a composite nano-particle which takes nano mesoporous silica (MSN) as a core and is formed by crosslinking fucoidin and rhodiola rosea polysaccharide; and d) the FP (at) EcN-pnirNKL is an oral delivery system which is formed by encapsulating the engineering bacterium EcN-pnirNKL in the FP nano particles. When the compound is applied to prevention and treatment of stress response of weaned piglets, various typical symptoms, including weight loss, colon shortening, histopathological injury and colitis disease response, of the piglets induced by dextran sodium sulfate can be remarkably relieved, and meanwhile, the integrity and functions of an intestinal barrier structure are effectively protected.

Disclosed is a biological control composition comprising a known molar amount of bacilysin, or a known and high ratio of bacilysin to fengycin, uses of said composition, a method for purifying bacilysin and a method for absolute quantification of bacilysin.

A general formula for lysins based on which the activity and functionality are further screened and 24 lysins are identified and further investigated, nine of which are characterized. These lysins exhibit potent bactericidal activity, capable of lysing multiple species of Staphylococcus, Streptococcus, and / or Enterococcus; demonstrate robust environmental resistance and stability, retaining activity under varying temperatures, NaCl concentrations, pH levels, and in immune serum; and effectively treat localized and systemic infections. These lysins and their variants are promising as antimicrobial agents for eradicating bacteria, preventing bacterial infections, or treating bacterial infections (caused by genera Staphylococcus, Streptococcus, and / or Enterococcus).

This invention relates to recombinant lyases and variants thereof, which have improved stability or bactericidal activity relative to the recombinant lyases. This application also relates to pharmaceutical compositions comprising the recombinant lyases and variants thereof, and their use for the prevention and / or treatment of bacterial infections (e.g., bacterial vaginosis).

The invention relates to the technical field of biology, in particular to a pagrosomus major antibacterial peptide Pm-NK-lysin as well as a preparation method and application of the pagrosomus major antibacterial peptide Pm-NK-lysin. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO: 1. The minimum inhibitory concentration of the antibacterial peptide to vibrio anguillarum is not higher than 8 [mu] g / ml, and / or the minimum inhibitory concentration of the antibacterial peptide to escherichia coli is not higher than 4 [mu] g / ml. The antibacterial peptide is prepared through a pichia pastoris expression system. The antibacterial peptide is applied to preparation of an antibacterial preparation. According to the invention, efficient secretory expression of recombinant Pm-NK-lysin is successfully realized by creatively utilizing a pichia pastoris eukaryotic expression system, and a protein purification process is optimized, so that sufficient sources of high-activity recombinant protein are guaranteed. The Pm-NK-lysin provided by the invention has an excellent killing effect on aquatic pathogenic bacteria. The antibacterial peptide Pm-NK-lysin is used for replacing or reducing the use of antibiotics to control the harm of aquatic bacterial diseases, has wide popularization and application values, and certainly has far-reaching significance for promoting the green and healthy development of the aquaculture industry.

The present invention relates to compositions comprising RNA, preferably messenger RNA (mRNA), more preferably self-amplifying RNA (saRNA), and polymers, in particular cationic polymers, such as polyethylenimine (PEI), poly-L-Lysin (PEL), polyvinylamine (PVA) or polyallylamine (PAA), where individual RNA molecules are present in solution. In the formulations, the RNA is preferentially present in the form of monomers, dimers, timers or oligomers, but not as aggregates comprising a large number of RNA molecules per aggregate, in particular large polyplex nanoparticles. The formulations display improved transfection efficacy and they can be used for delivery of RNA to a subject, where they have an improved dose response relationship in comparison to formulations where large aggregates in the form of polyplex nanoparticles are present.

The application discloses a marine bacteriophage antibacterial lysin prediction method and device, medium and equipment, and relates to the fields of biological medicine and computational biology. The method comprises the following steps: constructing a training data set based on global known antibacterial protein sequences; training a protein sequence classification model based on deep learning by using the antibacterial protein data set to obtain a marine antibacterial lysin prediction model. After data standardization processing, the protein sequence of the bacteriophage to be predicted is input into the protein language model, the input sequence is subjected to self-attention modeling by a ProtT5 module, global structure and function related features are extracted, and a first feature vector is obtained; short sequence local dependency features are extracted by a ProtBERT module, and a second feature vector is obtained; the first and second feature vectors are weighted and summed to generate a fusion feature vector; and the fusion feature vector is subjected to probability prediction, and an antibacterial label and a prediction confidence of the marine bacteriophage sequence to be predicted are output.

The invention relates to the technical field of agricultural biology, in particular to an alpha spiral mutant of granulysin with improved antibacterial activity and application of the alpha spiral mutant. The amino acid sequence of the alpha spiral mutant peptide of granulysin with improved antibacterial activity is as shown in SEQ ID No: 2. According to the present invention, the antibacterial activity of the granulysin mutant on different bacteria such as gram-negative bacteria salmonella typhimurium, escherichia coli and salmonella pullorum is enhanced;

The present invention concerns antibody-conjugate having general structure (2):wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.

A formulation of conjugates of tubulysin analogs with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, , R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are as defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.

This invention discloses the Clostridium difficile phage recombinant lyase Lys51, its preparation method, and its application, relating to the field of genetic engineering technology. The invention involves introducing the recombinant plasmid pET-28a-SUMO-Lys51 into Escherichia coli BL21(DE3) competent cells via heat shock transformation; screening to obtain the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51; constructing the recombinant plasmid pET-28a-SUMO-Lys51 and the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, further inducing the expression of Clostridium difficile phage recombinant lyase Lys51 in the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, and then purifying it to achieve the complete process for preparing Clostridium difficile phage recombinant lyase Lys51.

The application discloses a recombinant bacillus Calmette-Guerin (BCG) strain and application of the recombinant BCG strain in preparation of a tumor vaccine, wherein the recombinant BCG strain comprises an HPV16 E7 antigen gene with a nucleotide sequence as shown in SEQ ID NO:1; a cytolysin ClyA gene is further fused with the HPV16 E7 to be expressed, and a rBCG-ClyA+E7 recombinant strain is constructed; the recombinant BCG strain rBCG-E7 or rBCG-ClyA+E7 is applied in preparation of a vaccine for treating cervical cancer solid tumors; the anti-tumor effect is verified in a solid tumor model through a subcutaneous injection mode; the ClyA significantly improves the expression efficiency of an exogenous antigen in the BCG, and simultaneously enhances the presentation efficiency of an antigen presenting cell; the recombinant vaccine effectively activates an anti-tumor immune response, and does not cause obvious toxic side effects, thereby providing a safe and effective candidate strategy for immunotherapy of cervical cancer and other HPV related solid tumors.

A formulation of conjugates of tubulysin analogs with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, ----, R1, R2, R3, R4, R1, R6, R7, R1, R9, R10, R11, R12, and R13 are as defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.

This invention relates to the field of agricultural biotechnology, specifically to the antimicrobial peptide chicken NK lysin mutant and its applications. The chicken NK lysin mutant of this invention is effective against various bacteria, such as Salmonella typhimurium (…). Salmonella typhimurium 541, Gram-negative bacteria), Escherichia coli ( Escherichia coli O157:H7 1491, Gram-negative bacteria), Gram-negative bacteria Salmonella pullorum ( salmonella pullorum ) and Staphylococcus aureus ( Staphylococcus aureus The antibacterial activity of ) is enhanced.

This invention relates to a phage lysin LysSPYS1, a composition containing the phage lysin, and their applications. The sequence of the phage lysin LysSPYS1 is shown in SEQ ID No. 1. This phage lysin exhibits highly efficient and broad-spectrum bactericidal activity; it has a lytic effect on a variety of bacteria and can be used as a bacteriostatic agent. Furthermore, combining this phage lysin with polymyxin B can exert a synergistic antibacterial effect, significantly reducing the amount of antibiotics used. The phage lysin can also be used in combination with magnolol to achieve a prominent antibacterial effect.

This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.

The invention relates to the technical field of biology, in particular to listeria monocytogenes bacteriophage lyase Lys039 and application, and the amino acid sequence of the lyase Lys039 is shown as SEQ ID NO.1; the lyase Lys039 has the cracking activity, and shows the cracking activity on all listeria; the molecular marker has a wide splitting spectrum, but cannot split staphylococcus, bacillus subtilis and gram-negative bacteria, and has specificity. The sterilization capability is relatively high, and the concentration dependence is realized; good temperature tolerance is achieved, and the highest temperature can reach 80 DEG C; the listeria monocytogenes strain has the advantages that the listeria monocytogenes strain shows bactericidal activity in the pH range of 3-12, the listeria monocytogenes viable count can be obviously reduced in both acidic and alkaline environments, and when the pH is 6, the listeria monocytogenes strain has higher activity and shows higher acid and alkali resistance.

Novel recombinant lysins and their use in the treatment of Gram-negative bacterial infections. The present invention relates to novel recombinant lysins and their use as antimicrobial agents in novel therapeutic approaches to eliminate antibiotic-resistant Gram-negative bacteria and minimize the emergence of new resistance. The present invention further relates to polynucleotides encoding the recombinant lysins of the invention, vectors and host cells comprising same, and related methods, medical uses, compositions and kits.

Clostridium difficile, reclassified as Clostridioides difficile, is a Gram-positive, spore-forming, anaerobic, and toxin-producing nosocomial pathogen. Since the first description of a C. difficile-associated disease (CDAD)-like case in 1892, C. difficile infection (CDI) has become a high-impact health care-associated infection throughout the world, especially in the developed countries. Described herein are methods of treating Clostridium difficile infection in a subject in need thereof by administering an amount of the engineered lysin-human defensin (LHD) protein(s) described herein.

This invention belongs to the field of hydrogel microneedle preparation technology, specifically relating to a collagen microneedle patch loaded with a novel antibacterial lysin, its preparation method, and its application. The steps are as follows: First, using a novel antibacterial lysin (PlyAB1) and elastin-like protein (ELP) as raw materials, PlyAB1@ELP antibacterial aggregates are prepared. Then, the PlyAB1@ELP aggregates are incorporated into a DNA-recombinant XVII collagen (rCol XVII) dual-network hydrogel to prepare a DNA-rCol XVII dual-network hydrogel loaded with the novel antibacterial lysin. Finally, the mixed hydrogel is laid in a PDMS mold, and after vacuum treatment, centrifugation, and drying, a collagen microneedle patch loaded with the novel antibacterial lysin (PlyAB1@ELP@MN) is obtained. The PlyAB1@ELP@MN of this invention exhibits excellent antibacterial properties and skin regeneration and repair capabilities, and can be used to treat bacterial infections and promote wound healing.

This invention provides a nanopore detection device, as well as a method and application for detecting biological samples using this device. The nanopore detection device includes an insulator with openings, a phospholipid membrane or polymer membrane located within the openings, nanopores formed by mutant aeromonas lysin passing through the phospholipid membrane or polymer membrane, chambers located on opposite sides of the insulator, an electrolyte contained within the chambers, and a detector disposed within the chambers. The nanopore technology developed in this application enables efficient qualitative or rapid quantitative detection of one or more samples—such as one or more angiotensin peptides—and achieves significant improvements in resolution, sensitivity, capture efficiency, and matrix compatibility. The nanopore technology developed in this application also enables real-time quantitative monitoring of the dynamic changes of one or more samples—such as one or more angiotensin peptides.

This invention discloses the endolysin LysC75 of Vibrio parahaemolyticus phage and its applications. The amino acid sequence of endolysin LysC75 is shown in SEQ ID NO.2. The bactericide provided by this invention, with endolysin as the main active substance, can efficiently lyse Vibrio parahaemolyticus, with an effective bactericidal concentration of ≥0.2 mg / mL. When the bactericide with an endolysin concentration of 1 mg / mL is applied for 120 min, it can reduce the concentration of high-level Vibrio parahaemolyticus from 10... 8 CFU / mL dropped to 10 5 CFU / mL. A concentration of 1 mg / mL of this fungicide is effective against ≤10 3 The bactericidal effect of CFU / mL on Vibrio parahaemolyticus is 100%, and it is effective against 10... 6 -10 4 The sterilization rate of CFU / mL strains can reach over 90%, and for 10 9 -10 6 The bactericidal rate of CFU / mL strains can reach over 90%. This bactericide has high specificity against Vibrio parahaemolyticus and high lysis efficiency, providing an important alternative strategy for the control of drug-resistant Vibrio parahaemolyticus.

Novel recombinant lysins and their use in the treatment of Gram-negative bacterial infections. The present invention relates to a novel recombinant lysin and its use as an antimicrobial agent in a novel therapeutic method for eliminating antibiotic-resistant gram-negative bacteria and minimizing the appearance of new drug resistance. The invention further relates to polynucleotides encoding the recombinant lysins of the invention, carriers and host cells comprising the same, as well as related methods, medical uses, compositions and kits.

The invention relates to the technical field of biology, in particular to a fusion protein, mRNA for coding the fusion protein and application of the fusion protein to inhibition of mycobacterium tuberculosis. The invention provides a fusion protein based on an antibacterial peptide combination and bacteriophage pigtail fiber protein or lysin and mRNA for coding the fusion protein, the mRNA can effectively express the antibacterial peptide and the bacteriophage pigtail fiber protein / lysin in macrophages, and after being infected with mycobacterium tuberculosis, the mRNA can effectively express the antibacterial peptide and the bacteriophage pigtail fiber protein / lysin. The antibacterial peptide combination carried by the phage pigtail fiber protein / lysin expressed in the cells specifically targets and kills the mycobacterium tuberculosis, so that the aim of removing the mycobacterium tuberculosis in the cells is fulfilled. Compared with the existing antituberculous drugs, the mRNA preparation disclosed by the invention can be massively expressed in cells, the expression duration is long, and mycobacterium tuberculosis of the cells can be effectively eliminated.

This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.

The present invention concerns antibody-conjugates which are especially suitable for the targeting of PTK7-expressing cells, in particular tumour cells. The antibody-conjugates according to the invention have structure (1):Herein, AB is an antibody capable of targeting PTK7-expressing tumours; L is a linker that links Z to D; Z is a connecting group; L6 is -GlcNAc(Fuc)w-(G)j-S-(L7)w′-, wherein G is a monosaccharide, j is an integer in the range of 0-10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine and Fuc is fucose, w is 0 or 1, w′ is 0, 1 or 2 and L7 is —N(H)C(O)CH2—, —N(H)C(O)CF2— or —CH2—; D is selected from the group consisting of anthracyclines, camptothecins, tubulysins, enediynes, amanitins, duocarmycins, maytansinoids, auristatins, eribulins, BCL-XL inhibitors, hemiasterlins, KSP inhibitors, TLR agonists, indolinobenzodiazepine dimers or pyrrolobenzodiazepine dimers (PBDs), and analogues or prodrugs thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further concerns a method for preparing the antibody-conjugates of structure (1) and application of the antibody-conjugates of structure (1).

Disclosed herein are methods of inhibiting the growth, reducing the population, or killing of at least one species of Gram-negative bacteria comprising contacting the bacteria with a composition comprising an effective amount of a Chp peptide, lysin, or lysin-AMP construct or active fragments or variants thereof for a period of time sufficient to inhibit said growth, reduce said population, or kill said at least one species of Gram-negative bacteria. Also disclosed herein are methods of inhibiting a Gram-negative bacteria present in sputum; methods of preventing, disrupting or eradicating a Gram-negative bacterial biofilm; and methods of treating a bacterial infection caused by a Gram-negative bacteria.

The present invention is generally in the fields of pharmaceuticals, in particular antibacterials, and protein engineering. In particular, the present invention relates to peptidoglycan hydrolases such as endolysins and nucleic acids, e.g., RNAs, encoding the peptidoglycan hydrolases of the invention, as well as medical uses thereof, for example, for treating diseases caused by and / or associated with a Staphylococcus (e.g., S. aureus) infection.

The present invention relates to the field of anti-infection treatment and prevention. The present invention relates to a bacteriophage lysin chimera or a variant thereof and a use thereof. The bacteriophage lysin chimera or the variant thereof of the present invention comprises a catalytic domain, a binding domain and a linker. The lysin and the chimera thereof of the present invention have improved biophysical properties, have excellent applicability, and are suitable for cosmetics, medical devices, disinfectants and / or therapeutic applications.

The invention provides a staphylococcus aureus competent cell preparation method, which comprises: 1) culturing staphylococcus aureus to obtain a staphylococcus aureus bacterial liquid; and 2) treating the staphylococcus aureus bacterial liquid by using a treating agent, and performing post-treatment to obtain the staphylococcus aureus competent cells, the treatment agent comprises lysostaphin. The invention provides a preparation method of a staphylococcus aureus competent cell, so that staphylococcus aureus enters a competent form and is in a state of efficiently accepting plasmids, and the reagent cost, the equipment cost and the time cost of staphylococcus aureus plasmid transfection can be reduced.